| Ezetimibe | cardiovascular prevention, in all type of patients | vs placebo (on top statins) | NS | NS | by 13% | NS | - | - | NS | - | by 6% | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.99 [0.91 1.07] | p=1.00 | 0 | 18144 | 1 | IMPROVE-IT, | | Coronary death | 0.96 [0.84 1.09] | p=1.00 | 0 | 18144 | 1 | IMPROVE-IT, | | Coronary event | 0.87 [0.80 0.95] | p=0.04 | 0 | 18144 | 1 | IMPROVE-IT, | | Cardiovascular death | 1.00 [0.89 1.13] | p=1.00 | 0 | 18144 | 1 | IMPROVE-IT, | | Fatal stroke | no data | | Cancer | no data | | stroke (fatal and non fatal) | 0.86 [0.73 1.01] | p=1.00 | 0 | 18144 | 1 | IMPROVE-IT, | | myocardial infarction (fatal and non fatal) | no data | | cardiovascular events | 0.94 [0.89 0.99] | p=0.04 | 0 | 18144 | 1 | IMPROVE-IT, | | Allergic reactions | no data | | End stage renal disease | no data | | carotide IMT | no data | | serious adverse events | no data | | death from all causes as adverse event | no data | | cardiovascular events as adverse event | no data | | Muscle-related adverse events | no data | | Neurocognitive disorder | no data | | neurological SAE | no data | | myocardial infarction as adverse event | no data | | cardiovascular death as adverse event | no data | | unstable angina as adverse death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| IMPROVE-IT, 2014 | 10 mg/day of ezetimibe and 40 mg/day of simvastatin | simvastatin 40 mg/day | subjects with stabilized high-risk acute coronary syndrome |
|
| Alirocumab | cardiovascular prevention, in all type of patients | vs placebo (on top statins) | by 15% | NS | by 12% | NS | - | - | - | - | by 13% | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.85 [0.73 0.98] | p=0.04 | 0 | 18924 | 1 | ODYSSEY OUTCOMES, | | Coronary death | 0.92 [0.76 1.11] | p=1.00 | 0 | 18924 | 1 | ODYSSEY OUTCOMES, | | Coronary event | 0.88 [0.80 0.96] | p=0.04 | 0 | 18924 | 1 | ODYSSEY OUTCOMES, | | Cardiovascular death | 0.88 [0.74 1.05] | p=1.00 | 0 | 18924 | 1 | ODYSSEY OUTCOMES, | | Fatal stroke | no data | | Cancer | no data | | stroke (fatal and non fatal) | no data | | myocardial infarction (fatal and non fatal) | no data | | cardiovascular events | 0.87 [0.81 0.94] | p=0.04 | 0 | 18924 | 1 | ODYSSEY OUTCOMES, | | Allergic reactions | no data | | End stage renal disease | no data | | carotide IMT | no data | | serious adverse events | no data | | death from all causes as adverse event | no data | | cardiovascular events as adverse event | no data | | Muscle-related adverse events | no data | | Neurocognitive disorder | no data | | neurological SAE | no data | | myocardial infarction as adverse event | no data | | cardiovascular death as adverse event | no data | | unstable angina as adverse death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| ODYSSEY OUTCOMES, 2018 | Alirocumab (on top intensive or maximum-tolerated statin therapy) | placebo | Post-ACS patients (1 to 12 months)with elevated levels of atherogenic lipoproteins despite intensive or maximum-tolerated statin therapy |
|
| Evolocumab | cardiovascular prevention, in all type of patients | vs placebo (on top statins) | NS | - | - | NS | - | - | by 21% | by 27% | by 20% | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 1.04 [0.91 1.19] | p=1.00 | 0 | 27564 | 1 | FOURIER, | | Coronary death | no data | | Coronary event | no data | | Cardiovascular death | 1.05 [0.88 1.25] | p=1.00 | 0 | 27564 | 1 | FOURIER, | | Fatal stroke | no data | | Cancer | no data | | stroke (fatal and non fatal) | 0.79 [0.66 0.95] | p=0.04 | 0 | 27564 | 1 | FOURIER, | | myocardial infarction (fatal and non fatal) | 0.73 [0.65 0.82] | p=0.04 | 0 | 27564 | 1 | FOURIER, | | cardiovascular events | 0.80 [0.73 0.88] | p=0.04 | 0 | 27564 | 1 | FOURIER, | | Allergic reactions | no data | | End stage renal disease | no data | | carotide IMT | no data | | serious adverse events | no data | | death from all causes as adverse event | no data | | cardiovascular events as adverse event | no data | | Muscle-related adverse events | no data | | Neurocognitive disorder | no data | | neurological SAE | no data | | myocardial infarction as adverse event | no data | | cardiovascular death as adverse event | no data | | unstable angina as adverse death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| FOURIER, 2017 | evolocumab (either 140 mg every 2 weeks or 420 mg monthly) | placebo | patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving statin therapy |
|
